Could a daily pill prevent psychosis? new trial begins

NCT ID NCT07226895

Recruiting now Disease control Sponsor: Monument Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing an experimental drug called MT1988 in 150 people aged 17 to 30 who are at high risk of developing psychosis. Participants take either a low dose, high dose, or placebo pill twice daily for 8 weeks. The main goal is to see if certain tests (like memory and symptom checklists) can detect changes caused by the drug, which will help design future larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MT1988 (an experimental drug taken as a pill twice daily)
What this could lead to: If this trial works, it could point toward a treatment that reduces symptoms and improves thinking in people at high risk for psychosis.
What could go wrong: This is a very early (Phase 1/2) trial with only 150 people. The drug may not work better than placebo, and side effects are unknown. It is designed mainly to find good tests for future studies, not to prove the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL HIGH RISK FOR PSYCHOSIS (CHR)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02115, United States
Columbia University
RECRUITING

New York, New York, 10032, United States
Icahan School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10128, United States
Northwell Health
RECRUITING

Glen Oaks, New York, 11004, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Prevention Science Institute
RECRUITING

Eugene, Oregon, 97403, United States
Temple University
RECRUITING

Philadelphia, Pennsylvania, 19122, United States
University of California
RECRUITING

Los Angeles, California, 90095, United States
University of California, Irvine
RECRUITING

Irvine, California, 92697, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94107, United States
University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh School of Medicine
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States
Yale University Conneticut Mental Health Center
RECRUITING

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.